p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.
暂无分享,去创建一个
[1] D. English,et al. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. , 1998, The American Journal of dermatopathology.
[2] R. Maestro,et al. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression , 1997, International journal of cancer.
[3] J. Bartek,et al. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.
[4] R. Kerbel,et al. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. , 1996, The American journal of pathology.
[5] C. Moskaluk,et al. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. , 1996, Human pathology.
[6] S. Semba,et al. EXPRESSION OF CYCLIN‐DEPENDENT KINASE INHIBITOR p21WAF1/CIP1 IN NON‐NEOPLASTIC MUCOSA AND NEOPLASIA OF THE STOMACH: RELATIONSHIP WITH p53 STATUS AND PROLIFERATIVE ACTIVITY , 1996, The Journal of pathology.
[7] U. Kees,et al. Deletions of the p16 gene in pediatric leukemia and corresponding cell lines. , 1996, Oncogene.
[8] E. Hovig,et al. Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. , 1996, British Journal of Cancer.
[9] C. Shields,et al. Deletion mapping of chromosome region 9p21‐p22 surrounding the CDKN2 locus in melanoma , 1996, International journal of cancer.
[10] T. Saida,et al. Immunohistochemical detection of CDK4 and 9 16INK4 proteins in cutaneous malignant melanoma , 1996, The British journal of dermatology.
[11] M. Inganäs,et al. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma. , 1996, British Journal of Cancer.
[12] Z. Su,et al. Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. , 1995, Oncogene.
[13] R. Kratzke,et al. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. , 1995, Cancer research.
[14] B. Peters,et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. , 1995, Oncogene.
[15] J. Herman,et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. , 1995, Cancer research.
[16] R. Hruban,et al. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. , 1995, The American journal of pathology.
[17] X. Estivill,et al. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene. , 1995, American journal of human genetics.
[18] N. Hayward,et al. Mutations and defective expression of the WAF1 p21 tumour‐suppressor gene in malignant melanomas , 1995, Melanoma research.
[19] C. Bartram,et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. , 1995, Blood.
[20] F. Haluska,et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.
[21] K. Kinzler,et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. , 1995, Cancer research.
[22] James M. Roberts,et al. Inhibitors of mammalian G1 cyclin-dependent kinases. , 1995, Genes & development.
[23] F. Mandelli,et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. , 1995, Blood.
[24] R. Eeles,et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. , 1995, The American journal of pathology.
[25] B. Vogelstein,et al. Absence of WAF1 mutations in a variety of human malignancies. , 1994, Blood.
[26] M. Pagano,et al. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. , 1994, Cancer research.
[27] Ashutosh Kumar Singh,et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. , 1994, Cancer research.
[28] W. Clark,et al. Germline p16 mutations in familial melanoma , 1994, Nature Genetics.
[29] Y. Xiong,et al. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. , 1994, Oncogene.
[30] D. Givol,et al. Induction of WAF1/CIP1 by a p53-independent pathway. , 1994, Cancer research.
[31] D. Elder,et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. , 1994, Oncogene.
[32] M. Skolnick,et al. A cell cycle regulator potentially involved in genesis of many tumor types. , 1994, Science.
[33] David Beach,et al. p21 is a universal inhibitor of cyclin kinases , 1993, Nature.
[34] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[35] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[36] D. Beach,et al. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. , 1993, Molecular biology of the cell.